Pharmacokinetic Study of Synera™ in Neonates and Infants

• Status: Suspended
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZARS Pharma Inc.
• Treatments: Lidocaine; Tetracaine

Criteria

Inclusion Criteria:

• Subject must be an infant of 1 to 4 months of age and weigh at least 2.5 kg or a neonate of 0 to 4 weeks postnatal age with a gestation period of at least 37 weeks, and weigh at least 1.8 kg.

• Subject is scheduled to have a medically indicated minor superficial procedure for which topical local anesthesia would provide a benefit.

• Subject has or will have an indwelling vascular access catheter for blood sampling at the time of the procedure visit. The indwelling vascular access catheter placement must be necessary for medical reasons other than the purposes of this study.

• The additional blood draws for the purposes of this study do not pose more than a minor risk to the health and welfare of the subject.

Exclusion Criteria:

• Subject has known allergies or sensitivities to any component of Synera.

• Subject has clinically significant laboratory abnormalities.

• Subject has known multiple allergies that could indicate hypersensitive skin.

• Subject has known active atopic dermatitis at or near the patch application site.